HAMP and plasma cell myeloma: In the JJN-3 model of myeloma, however, treatment with BMPR1a-Fc resulted in an increase in serum haemoglobin, concomitant with a reduction in hepatic hepcidin gene expression (Supplementary Fig. 15).